NovaBay Pharmaceuticals Provides Second Quarter 2012 Financial Results

Recent Highlights
  • Received FDA guidance at successful end-of-phase 2a meeting for NVC-422 program for treating impetigo; phase 2b study to initiate in the third quarter 2012  
  • Expanded global Aganocide® patent estate with seven new patents  
  • Initiated BAYnovation Phase 2b study for adenoviral conjunctivitis with first patients enrolled in the U.S. Enrollment continues to grow on target.

EMERYVILLE, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing novel anti-infective products for the treatment and prevention of microbial infections, today reported second quarter financial results for the period ended June 30, 2012.

Dr. Ron Najafi, Chairman and CEO, remarked, "We have made significant progress across our development pipeline. NovaBay now has Phase 2b clinical trials underway for conjunctivitis and urinary catheter blockage and encrustation, UCBE, and we expect our partner, Galderma, to begin their global Phase 2b for impetigo by the end of Q3, 2012. Our phase 2b study for adenoviral conjunctivitis began enrolling patients during the quarter and enrollment will continue to grow through completion in Q2 next year. We've also completed our end of Phase 2a meeting with the FDA for our impetigo program with our partner Galderma and we believe we are on track to commence our phase 2b in the third quarter 2012."

Second Quarter Financial Results

As of June 30, 2012, the Company's cash, cash equivalents and short-term investments totaled $10.4 million, compared to $14.1 million at the end of 2011. This decrease in cash was anticipated as the Company began its Phase 2b conjunctivitis trial, provided support for Galderma regarding the Phase 2b impetigo trial and continued its clinical trial for NVC-422 in urinary catheter blockage and encrustation (UCBE).

NovaBay's license and collaboration revenue for the three and six months ended June 30, 2012,were $856,000 and $2.2 million, respectively, compared to $4.5 million and $7.0 million in the corresponding periods in 2011. This decrease was attributed to termination of the Company's agreement with former partner Alcon, for which NovaBay received semi-annual support payments and a $2.0 million termination payment in 2011.

Research and development (R&D) expenses decreased by 15% to $2.4 million for the three months ended June 30, 2012, and decreased by 19% to $4.6 million for the six months ended June 30, 2012, compared with the same periods in 2011.  This decrease was attributed to the termination of the research activities related to Alcon in 2011, partially offset by the increase in clinical activities as the Company began its Phase 2b trial in conjunctivitis, continued its UCBE trial and continued to scale up for the impetigo trial, which is expected to start in the third quarter of 2012.

NovaBay expects to incur increasing R&D expenses in 2012 and in subsequent years as it continues to advance its clinical programs in ophthalmology and urology.

General and administrative expenses remained relatively flat for the three and six months ended June 30, 2012, at $1.4 million and $2.9 million, as expected, compared to the same periods in 2011. 

Net loss for the three months ended June 30, 2012 was $2.2 million, compared to a net income of $425,000 for the same period in 2011.  Net loss for the six months ended June 30, 2012 was $4.8 million, compared to $1.6 million for the same period in 2011. This change was primarily a result of the license and collaboration revenue decrease noted above, offset to some degree by a noncash gain on warrants issued as part of our July 2011 financing and the reduction in research and development expenses resulting from the termination of the Alcon agreement in 2011.

2012 Highlights

About NovaBay Pharmaceuticals, Inc.

Going Beyond Antibiotics

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products.

Aganocide ® Compounds

NovaBay's first-in-class Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay's clinical development activities are focused on three disease areas:
  • Dermatology - Partnered with Galderma, a leading dermatology company, to develop a formulation of NVC-422 for treatment of highly contagious skin infection, impetigo, caused primarily by S. aureus and Group A Beta-hemolytic streptococci. A major global Phase 2b clinical study is planned for 2012.  
  • Ophthalmology - NovaBay is developing an eye drop formulation of NVC-422 for treating adenoviral conjunctivitis. Enrollment into a global Phase 2b clinical study has begun with top-line data expected in the first half of 2013.  
  • Urology NovaBay's urinary catheter irrigation solution containing NVC-422 is currently enrolling patients in its Phase 2 proof-of-concept clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and associated urinary tract infections. The Company reported positive data from Part A of this study and expects to announce top-line results from Part B later in 2012.

NeutroPhase ®

NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. We believe that NeutroPhase is the only patented pure hypochlorous acid solution available and has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers. For additional information, visit: www.neutrophase.com .

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the expected timing of enrollment and commencement of clinical trials, expected timing of receipt and announcement of results of clinical studies, and expected future financial results . Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay's progress:
 
NOVABAY PHARMACEUTICALS, INC.
(a development stage company)
CONSOLIDATED BALANCE SHEETS
     
  June 30, December 31,
  2012 2011
(in thousands, except per share data) (unaudited)  
ASSETS    
Current assets:    
Cash and cash equivalents  $ 4,653  $ 8,428
Short-term investments   5,720  5,710
Accounts receivable  9  3
Prepaid expenses and other current assets  506  417
Total current assets  10,888  14,558
Property and equipment, net   1,069  1,270
Other assets  117  135
TOTAL ASSETS  $ 12,074  $ 15,963
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Liabilities:    
Current liabilities:    
Accounts payable  $ 901  $ 472
Accrued liabilities   1,306  1,061
Deferred revenue  1,537  1,305
Total current liabilities  3,744  2,838
Deferred revenues -- non-current  539  945
Deferred rent  50  115
Warrant liability  2,128  2,721
Total liabilities  6,461  6,619
     
Stockholders' Equity:    
Preferred stock, $0.01 par value; 5,000 shares authorized; none outstanding at June 30, 2012 and December 31, 2011  —   — 
Common stock, $0.01 par value; 65,000 shares authorized at June 30, 2012 and December 31, 2011; 28,868 and 28,587 issued and outstanding at June 30, 2012 and December 31, 2011, respectively  289  286
     
Additional paid-in capital  43,427  42,386
Accumulated other comprehensive loss  (62)  (44)
Accumulated deficit during development stage  (38,041)  (33,284)
Total stockholders' equity  5,613  9,344
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $ 12,074  $ 15,963
 
 
NOVABAY PHARMACEUTICALS, INC.
(a development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
           
  Three Months Ended June 30, Six Months Ended June 30, Cumulative Period from July 1, 2002 (inception) to
(in thousands, except per share data) 2012 2011 2012 2011 June 30, 2012
Revenue:          
License and collaboration revenue  $ 856  $ 4,527  $ 2,172  $ 7,006  $ 52,771
Other revenues  15  —   19  11  45
Total revenue  871  4,527  2,191  7,017  52,816
           
Operating expenses:          
Research and development  2,378  2,769  4,642  5,689  55,513
General and administrative  1,368  1,318  2,909  2,833  36,563
Total operating expenses  3,746  4,087  7,551  8,522  92,076
Operating income (loss)  (2,875)  440  (5,360)  (1,505)  (39,260)
           
Non-cash loss (gain) on change in fair value of warrants  628  —   593  —   (139)
Other income (expense), net  27  (11)  22  (42)  1,443
           
Income (loss) before income taxes  (2,220)  429  (4,745)  (1,547)  (37,956)
Provision for income taxes  (6)  (4)  (12)  (16)  (85)
Net income (loss)  (2,226)  425  (4,757)  (1,563)  (38,041)
           
Other comprehensive gain (loss):          
Change in unrealized gains (losses) on available-for-sale securities  (20)  4  (18)  (9)  (62)
Total comprehensive income (loss)  $ (2,246)  $ 429  $ (4,775)  $ (1,572)  $ (38,103)
           
Net loss per share:          
Basic and diluted  $ (0.08)  $ 0.02  $ (0.17)  $ (0.07)  
Shares used in per share calculations:          
Basic and diluted  28,671  23,480  28,621  23,454  
CONTACT: Investors:         NovaBay Pharmaceuticals, Inc.         Thomas J. Paulson         Chief Financial Officer         510-899-8809         tjpaulson@NovaBaypharma.com                  Investors and Media:         The Ruth Group                  Stephanie Carrington / Nicole Greenbaum (Investors)         (646) 536-7017/7009         scarrington@theruthgroup.com / ngreenbaum@theruthgroup.com                  Victoria Aguiar (Media)         (646) 536-7013         vaguiar@theruthgroup.com

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Breakouts

3 Biotech Stocks Under $10 to Trade for Big Breakouts

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders